The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's CHRS on-body injector (OBI) presentation of Udenyca (pegfilgrastim-cbqv), solely due to an ongoing review of inspection findings at a third-party filler.
Coherus markets Udenyca (pegfilgrastim-cbqv), a biosimilar of Amgen Inc's AMGN Neulasta, a prescription medicine used to prevent neutropenia (a lack of certain white blood cells) caused by receiving chemotherapy.
The CRL did not identify any issues with the Udenyca Onbody clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing, and no additional data or trials have been requested.
Also Read: Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability.
Coherus also announced today that the FDA has completed the clinical study site inspections of three clinical sites in China that enrolled subjects in the two pivotal clinical trials supporting the toripalimab BLA for the treatment of metastatic or recurrent nasopharyngeal carcinoma (NPC) as first-line treatment or as second or greater line treatment.
Only one site received an FDA Form 483, with one observation noted. Coherus believes the observation is readily addressable. Coherus continues to anticipate potential approval for toripalimab by the end of 2023.
Price Action: CHRS shares are down 8.74% at $4.07 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
